Navigation Links
Wayne State researcher discovers antibiotic useful for localized treatment of bone wear
Date:8/9/2011

DETROIT Total joint replacement surgeries can help relieve joint pain common in people with conditions like osteoarthritis. But sometimes, the debris from prosthetic joints leads to aseptic loosening, or disintegration of surrounding bones. In 2009, a Wayne State University researcher determined that the anti-inflammatory antibiotic erythromycin can prevent and treat such disintegration. There was one caveat, however: there are side effects associated with long-term usage of erythromycin.

But Weiping Ren, M.D., Ph.D., associate professor of biomedical engineering in WSU's College of Engineering, has found a solution. Erythromycin can be administered directly at the site of bone breakdown, rather than orally, so the whole body is not affected. The details of Ren's study are published in the August 2011 issue of Clinical Orthopaedics and Related Research.

"Although oral erythromycin reportedly inhibits inflammation in patients with aseptic loosening, long-term systematic (oral) erythromycin treatment is not recommended," said Ren.

Used primarily for its antimicrobial properties, erythromycin is used to treat conditions like respiratory tract infections and whooping cough, both caused by harmful bacteria. In addition to fighting bacteria, erythromycin reduces inflammation, making it a successful treatment for aseptic loosening.

"But long-term systemic use of erythromycin raises concerns about various side effects, including bacterial resistance, liver damage and gastrointestinal discomfort," said Ren. "We hypothesized that it may be advantageous to restrict erythromycin delivery to the inflammatory tissue around the implant to avoid these side effects."

To test his idea, Ren implanted metal pins coated with erythromycin in the inflamed tissue surrounding the prosthetic joint. He measured bone growth and implant stability, both indicators of how well the prosthesis integrates with the bone, and analyzed microscopic images of the periprosthetic tissue the affected tissue surrounding the prosthesis.

Ren found that at very low doses about a quarter of the dose used for killing bacteria erythromycin effectively reduces aseptic loosening inflammation. "At the same time, we confirmed that oral erythromycin can be effectively delivered into the periprosthetic tissues, supporting our hypothesis that oral erythromycin can be used as one of the nonsurgical treatment methods to extend implant longevity," said Ren.

By extending implant longevity, localized erythromycin will safely treat aseptic loosening and reduce the likelihood that patients with the condition will need revision surgery. "Medical insurance costs will be greatly reduced, because revision surgery is much more expensive than primary surgery," said Ren.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
734-748-4207
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related biology news :

1. Genomatix gives a hand in the analysis of Wayne States sequencing projects
2. NextCAT Inc. secures $250,000 to commercialize biodiesel technology developed at Wayne State
3. NextCAT secures license agreement for advanced biofuel technology from Wayne State
4. Soy increases effectiveness of radiation at killing lung cancer, Wayne State study shows
5. Wayne State University chosen as Michigans sole participant in EcoCAR 2
6. Wayne State to study the role of vitamin D in African-Americans with high blood pressure
7. NC State researchers get to root of parasite genome
8. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
9. NC State takes lead in crime scene investigation training
10. Penn State receives new NASA astrobiology grant
11. Penn State researcher wins Entomological Society of America award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... Shoreline ... to the strain level, today announced that the company will debut a novel new ... 26-29. , The new product, Shoreline Biome's Rapid Prep kit, is a fast ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN ... cells from stem cells. The red blood cells are made utilizing a ... conditions, for transfusion therapy and replaces the need for a human blood donor. ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... lead the company’s new Business Development Department. The move, which is part of ... been previously serving as the company’s Senior Vice President where he oversaw its ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... , ... January 28, 2020 ... ... enterprise software solutions for biopharmaceutical R&D, today announced the release of ... Genedata’s focus on supporting the implementation of Multi-Attribute Methods (MAM) for characterizing ...
(Date:1/24/2020)... ... January 24, 2020 , ... The impact of new medicines, ... laboratory and clinical services during the first two decades of the 21st century ... Slone Partners celebrates its 20th anniversary this year, its evolution as ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and ... editing. The partners have agreed to co-develop and market a portfolio of CRISPR ... pre-clinical programs. Over the longer-term, the parties aim to develop a COBO branded ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... can achieve specific properties for use in harsh environments inside or outside of ... up to three metals or alloys to achieve specific properties such as corrosion-resistance, ...
Breaking Biology Technology: